Company intelligence / Profile preview
Raphas
Seoul, South Korearaphas.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Raphas has demonstrated preclinical proof-of-concept for its microneedle platform delivering peptides, allergens, and nucleic acids with preserved efficacy and stability. The company is actively seeking partners to advance programs into later-stage clinical trials and commercialization.
- Therapeutic areas
- ImmunologyMetabolic Disorders
- Modalities
- Microneedle-based drug delivery systemPeptides (e.g., GLP-1)Nucleic acids (DNA, mRNA)BiologicVaccine patchAllergen immunotherapy patch
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Actively seeking co-development/product commercialization/licensing partners globallyhistory of collaboration with raw material medicine corporations
Beyond the preview
Go deeper on Raphas.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Raphas.